Money · Lobbying reports · 119th Congress
S. 43
18 saved lobbying reports name S. 43.
18 reports
Confirmed from the official recordSenate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
Lobbying Disclosure Act reports, LDA.gov. This copy was read November 22, 2026 at 12:34 PM Eastern.
Reports that name this bill
The amount is what the report gives for the whole quarter: everything the registrant did for that client, all issues together. A linked name opens that organization’s page on this site.
| Registrant | Client | Amount for the whole quarter | Quarter | Filed | Report |
|---|---|---|---|---|---|
| SANOFI US SERVICES INC. | SANOFI US SERVICES INC | $1,250,000.00reported as expenses | July to September 2026 | Open the report | |
| RADIUS ADVOCACY, LLC | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $30,000.00reported as income | July to September 2026 | Open the report | |
| WILEY REIN LLP | FRESENIUS KABI USA LLC | $10,000.00reported as income | July to September 2026 | Open the report | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $7,040,000.00reported as expenses | July to September 2026 | Open the report | |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $1,530,000.00reported as expenses | July to September 2026 | Open the report | |
| COVINGTON & BURLING LLP | PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | $340,000.00reported as income | July to September 2026 | Open the report | |
| AMGEN, INC. | AMGEN INC | $3,150,000.00reported as expenses | July to September 2026 | Open the report | |
| NOVARTIS | NOVARTIS | $840,000.00reported as expenses | July to September 2026 | Open the report | |
| BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) | BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY) | $120,000.00reported as expenses | July to September 2026 | Open the report | |
| FRESENIUS KABI USA LLC | FRESENIUS KABI USA LLC | $630,000.00reported as expenses | July to September 2026 | Open the report | |
| FAEGRE DRINKER BIDDLE & REATH LLP | TEVA PHARMACEUTICALS USA, INC. | $60,000.00reported as income | July to September 2026 | Open the report | |
| COUNCIL FOR INNOVATION PROMOTION (C4IP) | COUNCIL FOR INNOVATION PROMOTION (C4IP) | $90,000.00reported as expenses | July to September 2026 | Open the report | |
| FIERCE GOVERNMENT RELATIONS | ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA) | $60,000.00reported as income | July to September 2026 | Open the report | |
| MEHLMAN CONSULTING, INC. | THE CAMPAIGN FOR SUSTAINABLE RX PRICING | $90,000.00reported as income | July to September 2026 | Open the report | |
| MEHLMAN CONSULTING, INC. | ASSOCIATION OF ACCESSIBLE MEDICINES | $60,000.00reported as income | July to September 2026 | Open the report | |
| AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA) | AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA) | $10,000.00reported as expenses | July to September 2026 | Open the report | |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | ASSOCIATION FOR ACCESSIBLE MEDICINES | $770,000.00reported as expenses | July to September 2026 | Open the report | |
| KAISER FOUNDATION HEALTH PLAN INC. | KAISER FOUNDATION HEALTH PLAN INC | $500,000.00reported as expenses | July to September 2026 | Open the report |